|
Nitroso Betahistine Impurity C
|
|
2
|
139
|
October 28, 2024
|
|
Use of L-cysteine as nitrite scavenging
|
|
6
|
273
|
October 25, 2024
|
|
Selection of Solvent and Positive Control Concentration for Enhanced AMES Test -Pub
|
|
0
|
113
|
October 14, 2024
|
|
Oral Liquid Formulations
|
|
4
|
194
|
October 14, 2024
|
|
🇸🇦 Saudi FDA requesting Nitrosamines Risk Assessments
|
|
5
|
1733
|
October 9, 2024
|
|
Dietary exposure assessment for volatile N-nitrosamines from food and beverages for the U.S. population -Pub
|
|
0
|
116
|
September 18, 2024
|
|
NDMA testing in metformin
|
|
5
|
235
|
September 9, 2024
|
|
Vildaglibtin and Metformin in combinationy
|
|
1
|
547
|
October 17, 2023
|
|
USP - CPCA Nitrosamines Case Study
|
|
7
|
1516
|
August 30, 2024
|
|
Resources to help educate reluctant excipient suppliers?
|
|
7
|
342
|
August 28, 2024
|
|
Seventh European Medicines Agency - Medicines for Europe annual bilateral meeting
|
|
1
|
106
|
August 27, 2024
|
|
Analytical methodologies to detect N-nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices -Pub
|
|
0
|
356
|
August 27, 2024
|
|
🇧🇷 Guideline for the control of Nitrosamines Rev. 4
|
|
24
|
1749
|
August 21, 2024
|
|
AI for NDSRI by Brazil regulatory
|
|
6
|
905
|
August 7, 2024
|
|
South African Health Products Regulatory Authority (Nitrosamines)
|
|
2
|
710
|
August 5, 2024
|
|
👨💻 Dashboard Containing Published AI Limits
|
|
32
|
3696
|
August 2, 2024
|
|
🇲🇽 Coming July Mexico Nitrosamines Guideline
|
|
5
|
481
|
August 2, 2024
|
|
Extension of the implementation deadline for "Self-inspection on Risks of Contamination with Nitrosamines in Drug" in Japan
|
|
2
|
209
|
July 30, 2024
|
|
The clinical and regulatory status of NDSRI: A global imperative -Pub
|
|
1
|
264
|
July 30, 2024
|
|
EMA/CHMP Concept paper on the revision of the guideline on the chemistry of active substances
|
|
4
|
601
|
July 29, 2024
|
|
Swissmedic updated requirements for dealing with potential nitrosamine impurities in medicinal products
|
|
2
|
529
|
February 1, 2024
|
|
Development and Manufacture of Oligonucleotides + Nitrosamines
|
|
0
|
284
|
July 24, 2024
|
|
🇪🇺 EMA/409815/2020 Rev.21 (19-Jul-24)
|
|
1
|
2822
|
July 22, 2024
|
|
ICH M7 plans to harmonize AI limits for Nitrosamines
|
|
1
|
316
|
June 13, 2024
|
|
Nitrosamines in food raise a health concern (EFSA)
|
|
7
|
1087
|
June 11, 2024
|
|
Update: EFPIA workflows for Quality Risk management Jun 2024 v03
|
|
2
|
925
|
June 4, 2024
|
|
🇰🇷 Case study on the Occurrence of Impurities in Pharmaceuticals (Focusing on NDMA Cases)
|
|
0
|
335
|
May 31, 2024
|
|
Justify the presence of amine in the API chemical structure
|
|
3
|
306
|
May 29, 2024
|
|
FDA releases FY23 GDUFA Science and Research Report
|
|
0
|
278
|
May 24, 2024
|
|
🇪🇺 EDQM - top 10 deficiencies observed in new CEP applications
|
|
0
|
952
|
March 14, 2024
|